πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 1,015 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 8940301

Breast tumor treatment with anti-CXCR1 compositions

THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Tue Jan 27 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8940298

High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and d

The Regents of the University of California Β· Granted Tue Jan 27 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8926969

Anti-CD38 antibodies

Takeda Pharmaceutical Company Limited Β· Granted Tue Jan 06 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 01 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8912185

Use of glutaric acid derivatives or the pharmaceutically acceptable salts thereof as anti-

OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU β€œPHARMENTERPRISES” Β· Granted Tue Dec 16 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 11 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8901279

Humanized antibodies with anti-tumor activity

TEVA PHARMACEUTICALS AUSTRALIA PTY LTD Β· Granted Tue Dec 02 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8901171

Compounds for suppressing a peripheral nerve disorder induced by an anti-cancer agent

Takeda Pharmaceutical Company Limited Β· Granted Tue Dec 02 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8889138

Anti-ADDL antibodies and uses thereof

Northwestern University Β· Granted Tue Nov 18 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8883500

Method of preparing adenosine-resistant anti-tumor T lymphocytes for adoptive immunotherap

Northwestern University Β· Granted Tue Nov 11 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 06 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8871206

Anti-human folate receptor beta antibodies and methods of use

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Oct 28 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 23 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8865175

Increasing anti-IL-1Ξ± antibodies in a subject

XBIOTECH INC. Β· Granted Tue Oct 21 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 16 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8858946

Method for inhibiting HIV-1 replication utilizing anti-GBV-C E2 antibodies

THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF VETERANS AFFAIRS Β· Granted Tue Oct 14 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 09 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8859512

Anti-viral pyrimidine nucleoside derivatives

University College Cardiff Consultants Limited Β· Granted Tue Oct 14 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 09 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8853247

Oligomer-nitroimidazole anti-infective conjugates

Nektar Therapeutics Β· Granted Tue Oct 07 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 02 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8846034

Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof

HALOZYME, INC. Β· Granted Tue Sep 30 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8846056

Anti-RSV immunogens and methods of immunization

The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control Β· Granted Tue Sep 30 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8841273

Methods and compositions for anti-EGFR treatment

The Board of Regents of the University of Texas System Β· Granted Tue Sep 23 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 18 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8834883

Anti-VEGF antibodies and uses thereof

VACCINEX, INC. Β· Granted Tue Sep 16 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 11 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8835613

Ξ²-mannosylceramide and stimulation of NKT cell anti-tumor immunity

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Sep 16 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 11 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8835167

Humanized anti-tag 72 CC49 for diagnosis and therapy of human tumors

The United States of America as Represented by the Secretary of the Department of Health and Human Services Β· Granted Tue Sep 16 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 11 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8829025

Anti-cancer compounds

Northwestern University Β· Granted Tue Sep 09 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 04 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8822196

Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of s

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Sep 02 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 28 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8816058

Polynucleotides encoding anti-CD100 antibodies or antigen-binding fragments thereof

VACCINEX, INC. Β· Granted Tue Aug 26 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 21 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8809341

2,4-pyrimidinediamine compounds and uses as anti-proliferative agents

Rigel Pharmaceuticals, Inc. Β· Granted Tue Aug 19 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 14 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8809502

Mutated anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells

The United States of America as Represented by the Secretary of the Department of Health and Human Services Β· Granted Tue Aug 19 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 14 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted